Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7120865
Reference Type
Journal Article
Title
Api88 Is a Novel Antibacterial Designer Peptide To Treat Systemic Infections with Multidrug-Resistant Gram-Negative Pathogens
Author(s)
Czihal, P; Binas, A; Koehler, G; De Spiegeleer, B; Martin, LL; Nolte, O; Straeter, N; Alber, G; Hoffmann, R; Knappe, D; Fritsche, S; Zahn, M; Berthold, N; Piantavigna, S; Mueller, Uwe; Van Dorpe, S; Herth, N; ,
Year
2012
Is Peer Reviewed?
Yes
Journal
ACS Chemical Biology
ISSN:
1554-8929
EISSN:
1554-8937
Publisher
AMER CHEMICAL SOC
Location
WASHINGTON
Page Numbers
1281-1291
PMID
22594381
DOI
10.1021/cb300063v
Web of Science Id
WOS:000306540400019
Abstract
The emergence of multiple-drug-resistant (MDR), bacterial pathogens in hospitals (nosocomial infections) presents a global threat of growing importance, especially for Gram-negative bacteria with extended spectrum beta-lactamase (ESBL) or the novel New Delhi metallo-beta-lactamase 1 (NDM-1) resistance. Starting from the antibacterial peptide apidaecin 1b, we have optimized the sequence to treat systemic infections with the most threatening human pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The lead compound Api88 enters bacteria without lytic effects at the membrane and inhibits chaperone DnaK at the substrate binding domain with a K-D of 5 mu mol/L. The Api88-DnaK crystal structure revealed that Api88 binds with a seven residue long sequence (PVYIPRP), in two different modes. Mice did not show any sign of toxicity when Api88 was injected four times intraperitoneally at a dose of 40 mg/kg body weight (BW) within 24 h, whereas three injections of 1.25 mg/kg BW and 5 mg/kg BW were sufficient to rescue all animals in lethal sepsis models using pathogenic E. coli strains ATCC 25922 and Neumann, respectively. Radioactive labeling showed that Api88 enters all organs investigated including the brain and is cleared through both the liver and kidneys at similar rates. In conclusion, Api88 is a novel, highly promising, 18-residue peptide lead compound with favorable in vitro and in vivo properties including a promising safety margin.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity